AJMC Staff

What we're reading, October 11, 2016: USPSTF recommendations maybe shouldn't be tied to insurance coverage; growing dispute over homeopathy research; and the harm of pharmaceutical companies' copay assistant programs.

What we're reading, October 10, 2016: Anthem will not cover Exondys 51, the first drug approved for treatment of Duchenne muscular dystrophy; big soda has sponsored 96 health and medical groups; and new Illinois program seeks to fill care gaps for working poor.

Highlights of our peer-reviewed research in the healthcare and mainstream press.

What we’re reading, October 7, 2016: providers brace for Hurricane Matthew; lead exposure in children has dropped; and most physicians would not apologize to their patient after a mistake.

What we're reading, October, 6, 2016: UnitedHealth is sued for allegedly overcharging on prescription drugs; the Obama administration could point consumers to remaining insurance options as insurers leave the Affordable Care Act exchanges; and human life spans may have it a ceiling.

While the researchers found a "modest risk" of diabetes associated with job insecurity, they said it pointed to the need for policies that promoted job stability and better wages.

What we’re reading, October 4, 2016: US healthcare system is the 50th most efficient out of 55; health agencies will spend Zika funds on vaccine trials and local prevention efforts; Americans have little confidence in their healthcare decisions as 69% say they are confused by terminology.

What we're reading, October 3, 2016: President Barack Obama's Affordable Care Act will have to change to survive; pharmacy benefit managers getting blamed for rising drug prices; and veterans could go without health insurance because states won't expand Medicaid.

What we're reading, September 30, 2016: HHS prioritized payments to Obamacare insurers over the Treasury; the CDC is concerned flu vaccinations may be down; and UnitedHealth Group and University of California come together for new partnership.

The uptick in BMI among professional baseball players coincides with the steroid era, although there were also advances in nutrition and training that could explain weight gain.

Highlights of our peer-reviewed research in the healthcare and mainstream press.

What we're reading, September 29, 2016: as part of the bill to prevent a government shutdown, the Senate has finally approved Zika virus funding; electronic health record breaches skyrocketed from 2014 to 2015; and California passes "right to try" law for terminally ill patients.

What we're reading, September 28, 2016: a new company will help people fight their medical bills; prescription drug monitoring programs may not be helping the opioid crisis; and why banning pay-for-delay deals may not help to lower costs.

What we're reading, September 27, 2016: a panel of experts recommends expanding preventive services for women with no cost sharing; BlueCross BlueShield of Tennessee is exiting 3 Obamacare exchanges; and Pfizer will not split into 2 companies.

What we're reading, September 26, 2016: the obesity rate in America has been rising steadily, but the health system is ill equipped to treat these patients; the pros and cons of mail-order medications; and barring recipients of federal funding from preventing money from going to Planned Parenthood.

Our peer-reviewed research in the healthcare and mainstream press.

What we're reading, September 23, 2016: California's insurance commissioner wants to try a public option; Valeant avoids double-digit price hikes with 9.9% increases; maker of Suboxone being sued by 35 states and the District of Columbia for keeping generics off the market.

What we're reading, September 22, 2016: a new bill would cap out-of-pocket costs for Medicare beneficiaries; world leaders agreed to a global effort to curb the spread of superbugs; and Mark Zuckerberg and Priscilla Chan, MD, will donate $3 billion over 10 years to cure disease.

What we're reading, September 21, 2016: Missouri law to charge Medicaid patients for missed doctor's appointments is in limbo; generic drugs' potential to bring down costs; fitness trackers cause people to lose less weight.

What we're reading, September 20, 2016: CDC reports widespread use of powerful antibiotics in hospitals; Gilead Sciences is backing advocates who want states to pay for expensive drugs; and Zika travel advisory lifted in 1 Florida zone.

Using prophylaxis with biosimilar granulocyte colony-stimulating factor can reduce the severity of neutropenia in patients with soft tissue sarcoma.

What we're reading, September 19, 2016: the government update rules on reporting clinical trial findings; hospitals say they aren't receiving discounts for Valeant's heart drugs; and the FDA approved the first treatment for Duchenne muscular dystrophy.

Highlights of our peer-reviewed research in the healthcare and mainstream press.

What we're reading, September 16, 2016: Donald Trump mentions using Medicaid to expand coverage and making birth control available without a prescription; medical marijuana could curb the opioid epidemic; and how rare diseases are becoming more common.

What we're reading, September 15, 2016: A United Nations panel challenges the market-based approach to drug research and development; an FDA panel recommends removing a serious health warning from Chantix's label; and older patients may want to wait to get their flu shot.

What we're reading, September 14, 2016: CMS denies Ohio's proposal to charge Medicaid fees; steep costs of healthcare continue to push Americans into poverty; and Canada approves prescription heroin to treat severe addiction.

Although daratumumab reduced the risk of disease progression and death for patients with multiple myeloma, the drug was associated with a higher rate of neutropenia.

What we're reading, September 13, 2016: GOP bill would exempt people who live in areas with 1 Obamacare plan or none from penalties for not having coverage; hepatitis C drugs threaten to bust prison budgets; and school challenges for children with mental illness.

FDA staff are not convinced that the smoking-cessation drugs varenicline (Chantix), developed by Pfizer, and bupropion (Zyban), developed by GSK, do not increase suicidal tendencies among users.

What we're reading, September 12, 2016: Hillary Clinton's health is being called into question as her campaign confirms she has pneumonia; responders who helped during the 9/11 terrorist attacks may be sick and not know it; and Sanofi and Google team up for a diabetes venture.